Sirius Capital
VC Fund
Beijing, China
Sirius Capital is a venture capital firm in China that invests in technology companies.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Sirius Capital invests in
Stages Sirius Capital invests in
Countries Sirius Capital invests in
Round sizes
Round size
- Seed
- $1.4M–$4.6M
- Series A
- $7M–$50M
Investment Focus
Industry
- Artificial Intelligence 8 (50%)
- Robotics 2 (13%)
- Health Care 2 (13%)
- Semiconductor 2 (13%)
- Machine Learning 2 (13%)
Stage
- Series A 5 (31%)
- Venture - Series Unknown 3 (19%)
- Seed 2 (13%)
- Series C 2 (13%)
- Angel 1 (6%)
Country
- China 13 (81%)
- Australia 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Zenbot
|
Zenbot is a high-growth startup specializing in embodied intelligence infrastructure. | $14.7M / Angel / May 14, 2026 | |
| Vantari VR provides procedural training for medicine and surgery. | $7M / Series A / Dec 07, 2023 | ||
| Vantari VR provides procedural training for medicine and surgery. | $4.6M / Seed / Dec 07, 2023 | ||
| Kuanfen Technology Realcome is a brand of AI virtual bloggers that focuses on the use of various AI technologies. | $1.4M / Seed / Nov 20, 2023 | ||
| Vastai Technologies is focused on developing AI chips for the optimization of computer vision and video processing. | $50M / Series A / Nov 30, 2020 | ||
| Founded in August 2014, Shenzhen TargetRx, Inc. is a Sino-American joint venture, high-tech pharmaceutical research and development company. When established, company won the investment from famous angel institutions in China with a registered capital of RMB 80 million. The company focuses on the research and development of targeted drugs, and aimsto become the world’s leading research and development platform for targeted drugs. Company founder, Dr. Yihan Wang graduated from New York University, is an internationally well-known medical expert, leader of overseas Chinese, and Shenzhen Peacock Plan B talent. He has over 16 years of oversea working experience in the field of small molecule targeted anti-cancer drugs, and is the key inventor of international forefront drugs, such as IClusig (Ponatinib), Alunbrig (Brigatinib), and Ridaforolimus. Dr. Wang has 27 authorized invention patents, and has published more than 60 papers. Headed by Dr. Wang, Shenzhen TargetRx, has devoted itself to the research and development of anti-tumor drugs and saving the life of cancer patients.With the global desideration of novel small molecule targeted anti-tumor drugs, Shenzhen TargetRx designs, screens, evaluates, optimizes, and researches original series of the 3rd generation small molecule anti-tumor drugs that have independent intellectual property rights. By doing so, Shenzhen TargetRx works to overcome the difficulty – acquired drug resistance, and strives to turn cancer from the No. 1 killer of human lives into chronic disease. | $14.8M / Venture - Series Unknown / Sep 18, 2020 | ||
| Shenzhen Yuntian Lifei Technology was established in August 2014 and is committed to structuring the physical world through AI technology to create a digital twin city. The company relies on a first-class international expert team and a "full stack" AI technology platform to create products and solutions for public safety, socialgovernance, new business, AIoT, and other fields, which have been widely used in Shenzhen, Beijing, Shanghai, Hangzhou, Qingdao, Chengdu, Dongguan, Southeast Asia, and more than 100 cities and regions | $141M / Series C / Apr 03, 2020 | ||
| Taotao Technology focuses on manufacturing in the field of advanced ceramics, R&D integration, and services | Jan 01, 2020 | ||
| Hangzhou Shutu Information Technology Co. develops industrial-IoT technologies to help industrial production and traditional industries. | Venture - Series Unknown / Jan 01, 2019 | ||
| Eigen is applying the latest AI technologies to variety of business domains, making AI the center of thegravity in industrial evolutions. | $6.6M / Series B / Nov 01, 2018 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sirius Capital invest in?
Sirius Capital invests primarily in Artificial Intelligence, Robotics and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sirius Capital's check size?
Sirius Capital typically joins rounds of $1.4M–$4.6M at Seed and $7M–$50M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sirius Capital participates in.
When did Sirius Capital last invest?
The most recent investment recorded for Sirius Capital closed in May 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
